Trusted Resources: News & Meetings
Latest announcements and gatherings
Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)
Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II). DNL310, Denali’s lead investigational brain-penetrant enzyme replacement therapy, is under evaluation in a Phase 1/2 study in patients with Hunter syndrome as a potential treatment for both central nervous system (CNS) and peripheral manifestations of the disease.
“Hunter syndrome is a devastating disease for which current approved treatments fail to effectively cross the blood-brain barrier and therefore do not address CNS symptoms,” said Carole Ho, M.D., Denali’s Chief Medical Officer.
BookmarkRelated Content
-
Golgi Requires a New Casting in the Screenplay of Mucopolysaccharidosis II CytopathologyLysosome (L), a hydrolytic compartment o...
-
Real World Long-Term Outcomes in Patients With Mucopolysaccharidosis Type II: A Retrospective Cohort StudyWe investigated the decline of activitie...
-
Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in KidsGene therapy might soon offer a new opti...
-
CHOP – Lysosomal Storage Disease (LSD) CenterThe Lysosomal Storage Disease Center at ...
-
Prenatal Diagnosis of Mucopolysaccharidoses Type II by Two-Dimensional Electrophoresis and Mass Spectrometry in Amni...To introduce a quantitative determinatio...
-
Stem Cell Transplant for Bridgnorth Boy With Rare ConditionTwenty-two-month-old Gunner, from Bridgn...
-
Treatment of Skeletal and Non-Skeletal Alterations of Mucopolysaccharidosis Type IVA by AAV-Mediated Gene TherapyMucopolysaccharidosis type IVA (MPSIVA) ...
Powered by
